Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947893 · ClinicalTrials.gov registry record · Phase 2
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02947893 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 37 participants.
The verdict
NCT02947893, a Phase 2 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition, and stabilization of CSF total Tau and p-Tau231/181 and Abeta42/40 levels. The investigators hypothesize that Nilotinib will decrease brain load of amyloid using amyloid positron emission tomography (PET). The investigators also predict that Nilotinib will reduce CSF markers of cell death, including neuron specific enolase (NSE) and S100B.
Interventions
- DRUG Placebo Capsule(s) Once a Day by Mouth
- DRUG Nilotinib Capsule(s) Once a Day by Mouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-01 |
| Est. Completion | 2021-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947893
The ClinicalTrials.gov registry entry for NCT02947893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Capsule(s) Once a Day by Mouth is the first listed.
NCT02947893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947893 about?
NCT02947893 is a clinical study titled "Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease". The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition, and stabilization of CSF total Tau and p-Tau231/181 and Abeta42/40 level...
What is the current status of trial NCT02947893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2017-01. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02947893?
The interventions under investigation include: Placebo Capsule(s) Once a Day by Mouth (DRUG), Nilotinib Capsule(s) Once a Day by Mouth (DRUG).
Who is sponsoring clinical trial NCT02947893?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.